These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Entrapment of small molecules and nucleic acid-based drugs in liposomes. Fenske DB; Cullis PR Methods Enzymol; 2005; 391():7-40. PubMed ID: 15721372 [TBL] [Abstract][Full Text] [Related]
4. Targeting liposomal nanomedicine to cancer therapy. Zhong J; Dai LC Technol Cancer Res Treat; 2012 Oct; 11(5):475-81. PubMed ID: 22475065 [TBL] [Abstract][Full Text] [Related]
5. Liposomal drug delivery systems: from concept to clinical applications. Allen TM; Cullis PR Adv Drug Deliv Rev; 2013 Jan; 65(1):36-48. PubMed ID: 23036225 [TBL] [Abstract][Full Text] [Related]
6. Anticancer drug delivery with nanoparticles. Conti M; Tazzari V; Baccini C; Pertici G; Serino LP; De Giorgi U In Vivo; 2006; 20(6A):697-701. PubMed ID: 17203748 [TBL] [Abstract][Full Text] [Related]
7. Advances in lipid nanodispersions for parenteral drug delivery and targeting. Constantinides PP; Chaubal MV; Shorr R Adv Drug Deliv Rev; 2008 Mar; 60(6):757-67. PubMed ID: 18096269 [TBL] [Abstract][Full Text] [Related]
8. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Bharali DJ; Mousa SA Pharmacol Ther; 2010 Nov; 128(2):324-35. PubMed ID: 20705093 [TBL] [Abstract][Full Text] [Related]
9. Multifunctional nanoparticles--properties and prospects for their use in human medicine. Sanvicens N; Marco MP Trends Biotechnol; 2008 Aug; 26(8):425-33. PubMed ID: 18514941 [TBL] [Abstract][Full Text] [Related]
10. Liposomal nanomedicines in the treatment of prostate cancer. Kroon J; Metselaar JM; Storm G; van der Pluijm G Cancer Treat Rev; 2014 May; 40(4):578-84. PubMed ID: 24216226 [TBL] [Abstract][Full Text] [Related]
11. Factors affecting toxicity and efficacy of polymeric nanomedicines. Igarashi E Toxicol Appl Pharmacol; 2008 May; 229(1):121-34. PubMed ID: 18355886 [TBL] [Abstract][Full Text] [Related]
12. Nanoparticle formulations in pulmonary drug delivery. Bailey MM; Berkland CJ Med Res Rev; 2009 Jan; 29(1):196-212. PubMed ID: 18958847 [TBL] [Abstract][Full Text] [Related]
13. Oral delivery of siRNA and antisense oligonucleotides. Akhtar S J Drug Target; 2009 Aug; 17(7):491-5. PubMed ID: 19530907 [TBL] [Abstract][Full Text] [Related]
15. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
16. SiRNA delivery: challenges and role of carrier systems. Shegokar R; Al Shaal L; Mishra PR Pharmazie; 2011 May; 66(5):313-8. PubMed ID: 21699063 [TBL] [Abstract][Full Text] [Related]
17. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Malam Y; Loizidou M; Seifalian AM Trends Pharmacol Sci; 2009 Nov; 30(11):592-9. PubMed ID: 19837467 [TBL] [Abstract][Full Text] [Related]
18. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Li SD; Huang L Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857 [TBL] [Abstract][Full Text] [Related]
19. Liposomes in ultrasonic drug and gene delivery. Huang SL Adv Drug Deliv Rev; 2008 Jun; 60(10):1167-76. PubMed ID: 18479776 [TBL] [Abstract][Full Text] [Related]
20. Lipid nanocapsules: a new platform for nanomedicine. Huynh NT; Passirani C; Saulnier P; Benoit JP Int J Pharm; 2009 Sep; 379(2):201-9. PubMed ID: 19409468 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]